Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Cheon, Gab Jin | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Kim, Boo Sung | - |
dc.contributor.author | Jun, Baek Gyu | - |
dc.contributor.author | Kim, Young Don | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Sohn, Joo Hyun | - |
dc.contributor.author | Kim, Tae Yeob | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.date.accessioned | 2021-08-11T13:43:54Z | - |
dc.date.available | 2021-08-11T13:43:54Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.issn | 2040-2058 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6817 | - |
dc.description.abstract | Background: A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV) therapy for nucleoside analogue-resistant chronic hepatitis B. Methods: Patients (n=60) were randomized to TDF monotherapy or ETV-ADV combination therapy for 96 weeks. All patients had the rt204I/V mutation and serum HBV DNA was measured (>60 IU/ml) during LAM-ADV therapy. The primary end point was a complete virological response (HBV DNA <20 IU/ml) at week 96. Results: The median duration of prior LAM-ADV rescue therapy was 43 (7-108) months. A complete virological response was achieved in 86.6% and 53.3% of patients in the TDF and ETV-ADV groups, respectively, at week 96 (P=0.005). Reduction in serum HBV DNA was significantly greater in the TDF group than in ETV-ADV group (-3.2 +/- 1.2 versus -2.6 +/- 1.2; P=0.01). Hepatitis B e antigen loss (22.2% versus 16.6%; P=0.731) and biochemical responses (76.7% versus 73.3%; P=0.766) were not different between the TDF and ETV-ADV groups. No newly emerged mutations were detected. Both therapies demonstrated favourable safety profiles. Conclusions: TDF therapy achieved a better complete virological response than ETV-ADV therapy in chronic hepatitis B patients with suboptimal response to long-term LAM-ADV rescue therapy. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | International Medical Press | - |
dc.title | Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.3851/IMP3169 | - |
dc.identifier.scopusid | 2-s2.0-85041730979 | - |
dc.identifier.wosid | 000454888400003 | - |
dc.identifier.bibliographicCitation | Antiviral Therapy, v.23, no.3, pp 219 - 227 | - |
dc.citation.title | Antiviral Therapy | - |
dc.citation.volume | 23 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 219 | - |
dc.citation.endPage | 227 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-B | - |
dc.subject.keywordPlus | LONG-TERM EFFICACY | - |
dc.subject.keywordPlus | ADD-ON THERAPY | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | PLUS LAMIVUDINE | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | ANALOG THERAPY | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | YMDD VARIANTS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | 의약학 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.